OXFORD, United Kingdom & CAMBRIDGE, Mass. (BUSINESS WIRE) Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announces that Mark Gaffney has been appointed as chief executive officer (CEO) and member of the Board.
Sequana Medical announces results of Special General Meeting of Shareholders finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
Appointment builds Oxular’s team as it prepares to enter human clinical studies evaluating OXU-001
OXFORD, UK, 8 February 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces that it has appointed Dr. Jatinder Kapur as Vice President of Quality.
His primary responsibilities include establishing and managing the Company’s Quality Management System, while also supporting other functions, as the Company prepares to enter human clinical studies evaluating OXU-001. OXU-001 is the Company’s 12-month treatment for inflammatory retinal diseases initially being evaluated for the treatment of Diabetic Macular Edema (DME). Dr. Kapur has been working with the Company as a consultant and will now join on a full-time basis.